Peripheral blood stem cell transplantation (PBSCT) requires a high-flow catheter for adequate cell collection by apheresis and long i.v. support, this is usually achieved by multiple catheters. We analyzed our experience with Mahurkar or Permacath for apheresis and long-term i.v. support in PBSCT, cared for exclusively by an i.v. therapy team. Fifty-six catheters were used in 53 @entity1 that completed PBSCT (28 Permacath and 28 Mahurkar). In 10 @entity1 (19%) the same catheter was used for multiple PBSCT. The average stay was 58.4 days (7-219), Permacath 76.8 days (14-219) and Mahurkar 42 days (7-106). The incidence of @entity166 complications was 2.2 x 1000 catheter-days (1.7 Permacath and 3.0 Mahurkar); during @entity1398 it was 3.7 x 1000 cathether-days. The incidence of @entity715 was 0.9 x 1000 catheter-days. There was a total of seven @entity166 episodes (12.7%). Five (9%) were local and two were (3.6%) @entity2259 . The microorganism most commonly isolated was Staphylococcus sp. (57%). Four catheters (7.1%) were removed because of complications: one @entity715 and three @entity281 . Both catheters have proven useful and safe for long-lasting vascular access in @entity1 undergoing PBSCT. No statistical difference was found in @entity166 and non- @entity166 complications between either catheters.

A single, double lumen high-flow catheter for XXXX undergoing peripheral blood stem cell transplantation. Experience at the National Cancer Institute in Mexico.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious'] @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremias']
@entity1 :: (9606,Species) :: ['patients']
